CHERYL PASSANISI: Open Payments
NPI 1497122360 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,804 in 53 payments from 17 companies in 2025. Trend: 2023 $665 · 2024 $1,055 · 2025 $1,804
Food & beverage: $1,804
| Company | Payments | Amount |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 6 | $256 |
| E.R. Squibb & Sons, L.L.C. | 2 | $249 |
| Daiichi Sankyo Inc. | 12 | $244 |
| Syndax Pharmaceuticals, Inc. | 3 | $195 |
| Janssen Biotech, Inc. | 5 | $185 |
| PharmaEssentia USA Corporation | 5 | $165 |
| BeOne Medicines USA, Inc. | 4 | $123 |
| AstraZeneca Pharmaceuticals LP | 3 | $70 |
| Merck Sharp & Dohme LLC | 2 | $55 |
| Kite Pharma, Inc. | 2 | $54 |
Products named: OPDIVO, BESREMI, REVUFORJ, Vanflyta, TAVALISSE, BRUKINSA, REZLIDHIA, TALVEY.
Industry payments across CA — which companies pay providers there.
